Candel Therapeutics (CADL) Shares Soar 9.60%

Candel Therapeutics (CADL) shares surged 9.60%, reaching their highest level since March 2025, with an intraday gain of 10.24%.

The strategy of buying CADL shares after they reached a recent high and selling them one week later delivered moderate returns but came with significant volatility and risk. Over the past five years, the strategy achieved a 129.37% return, vastly outperforming the benchmark return of 58.03%. However, it underperformed in terms of Sharpe ratio and experienced a maximum drawdown of 180.55%, indicating substantial volatility and risk.

Analysts have given Candel Therapeutics a "Strong Buy" rating, with an average price target of $22.60, indicating a substantial upside from current levels. Brookline Capital Management also maintains a "Strong-Buy" rating for the company.

Despite a 2.80% decrease in the stock price on the last trading day, the stock is positioned in the upper part of a rising trend in the short term. Both short and long-term moving averages are showing buy signals, suggesting potential for positive performance.

The stock is considered high risk due to its volatility, but it presents a potential buying opportunity due to its proximity to support levels. The general trend and analyst ratings suggest a positive outlook for Candel Therapeutics in the short term.